27th Feb 2020 14:09
(Alliance News) - Liquid biopsy company Angle PLC on Thursday said its Parsortix blood sampling system "greatly out-performed" an alternative approach when used on patients with renal cell carcinoma, a type of kidney cancer.
The research, published by an institute in Milan, Italy, assessed the performance of Parsortix with another circulating tumour cell testing system.
CTCs are cells which form a cancer tumour area and move to other parts of the body.
Angle added: "The Parsortix system greatly out-performed the alternative approach and, being a marker-independent approach for CTC enrichment, it was described in the publication as being 'instrumental for increasing CTC detection and for being able to separately identify the sub-populations by immunostaining'."
Angle Chief Executive Andrew Newland added: "This publication adds to the body of evidence demonstrating the strong advantages of the Parsortix system identifying new potential uses of the system to improve the care of cancer patients."
Angle shares were marginally lower at 61.99 pence each in London on Thursday afternoon.
By Eric Cunha; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Angle